MedTrace Logo

European Study of Opioid Induced Constipation

NCT05149833 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2025-04-03

No results posted yet for this study

Summary

Constipation is common (40-90%) in advanced cancer patients , and has a significant negative impact on quality of life. The aetiology of constipation is often multifactorial in advanced cancer patients. However, it is well recognised that opioid analgesics are a common cause of constipation in this group. The prevalence of opioid-induced constipation (OIC) is stated to be 40-70%, although a recent large study reported an even higher figure.

OIC has been reported to exceed pain in terms of distress caused, and studies have found that some patients choose to reduce or discontinue opioid medication in order to attempt to better control constipation. Moreover, OIC is associated with a variety of physical (gastrointestinal, systemic), psychological and social problems.

Conditions

  • Opioid-Induced Constipation

Sponsors & Collaborators

  • University of Dublin, Trinity College

    lead OTHER

Principal Investigators

  • Andrew Davies, MD · University of Dublin, Trinity College

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-16
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05149833 on ClinicalTrials.gov